Back

Ivabradine is not associated with higher risk of new onset atrial fibrillation among patients with cardiac resynchronization therapy

27 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Arrhythmia and cardio protection pharmacotherapy Cardiovascular Pharmacotherapy, Other ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor James Milner

Hospital Center of Entre Douro and Vouga, Santa Maria da Feira (Portugal)

5 More presentations in this session

Presentation thumbnail
Mr S. Kjeldsen (Gentofte, DK)
Abstract
Presentation thumbnail
Ms P. Madhavapeddi (Newark, US)
Abstract Slides
Presentation thumbnail
Miss C. Citerni (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Doctor D. Liu (Beijing, CN)
Abstract
Presentation thumbnail
Assistant Professor M. Kiyokuni (Yokohama, JP)
Abstract

Access the full session

Session thumbnail
Poster Session 4 - Arrhythmia and cardio protection pharmacotherapy

The Event

Event poster

ESC Congress 2018

27 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Session
How to treat arrhythmias in heart failure
17 May 2025
thumbnail
Congress Presentation
Ranolazine is associated with a reduced incidence of atrial fibrillation in patients with chronic coronary syndrome: the results of a real-world analysis of an Italian population
25 August 2023
thumbnail
Congress Presentation
The effect of add-on Ivabradine in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials and real-world data
21 May 2023
thumbnail
Congress Presentation
Atrial fibrillation in patients with acute coronary syndrome under clopidogrel versus ticagrelor.
13 March 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources